CIK 0001357459
- Non-accelerated filer
- Smaller reporting company
PALISADE BIO, INC.
Sign in to watch- Ticker
- PALI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 522007292
- Phone
- +1 858-704-4900
- Business address
- 7750 EL CAMINO REAL, SUITE 5200, CARLSBAD, CA, 92009
- Former names
- PALISADE BIO, INC., Seneca Biopharma, Inc., Neuralstem, Inc.
- Open-market buys, last 90 days
- $28,800
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$28,800. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 87 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-06 | Finley John David CEO CFO | Exercise or conversion | +3,227,384 | 3,356,672 | ||
| 2026-10-06 | Finley John David CEO CFO | Shares withheld for taxes | −1,411,982 | $1.49 | $2.1M | 1,944,690 |
| 2026-10-06 | Finley John David CEO CFO | Exercise or conversion · Restricted Stock Units | −3,059,800 | 6,119,600 | ||
| 2026-10-06 | Finley John David CEO CFO | Exercise or conversion · Restricted Stock Units | −167,584 | 1,508,249 | ||
| 2026-08-19 | Finley John David CEO, CFO | Gift | −88,400 | 129,288 | ||
| 2026-08-19 | Finley John David CEO, CFO | Gift | +88,400 | 88,451 | ||
| 2026-07-07 | Finley John David CEO, CFO | Sale | −146,798 | $2.07 | $303K | 217,555 |
| 2026-07-07 | Finley John David CEO, CFO | Exercise or conversion | +133 | $0.70 | $93 | 217,688 |
| 2026-07-07 | Finley John David CEO, CFO | Exercise or conversion · Series 2 Common Stock Purchase Warrant | −133 | 0 | ||
| 2026-07-06 | Finley John David CEO, CFO | Exercise or conversion | +335,167 | 364,353 | ||
| 2026-07-06 | Finley John David CEO, CFO | Exercise or conversion · Restricted Stock Units | −335,167 | 1,675,833 | ||
| 2026-02-12 | Finley John David CEO, CFO | Sale | −3,896 | $1.75 | $7K | 27,353 |
| 2026-02-11 | Finley John David CEO, CFO | Exercise or conversion | +13,333 | 31,249 | ||
| 2026-02-11 | Finley John David CEO, CFO | Exercise or conversion · Restricted Stock Units | −13,333 | 26,667 | ||
| 2026-02-09 | Finley John David CEO, CFO | Grant or award · Restricted Stock Units | +2,011,000 | 2,011,000 | ||
| 2025-10-06 | Finley John David CEO, CFO | Grant or award · Restricted Stock Units | +9,179,400 | 9,179,400 | ||
| 2025-09-04 | Finley John David CEO, CFO | Grant or award · Phantom Units | +323,400 | 323,400 | ||
| 2025-02-11 | Finley John David CEO, CFO | Grant or award · Stock Option (Right to Buy) | +47,000 | 47,000 | ||
| 2025-02-11 | Finley John David CEO, CFO | Grant or award · Restricted Stock Units | +40,000 | 40,000 | ||
| 2024-05-28 | Finley John David CEO, CFO, Director | Exercise or conversion | +1,622 | 10,059 |
Page 1 of 6 · 112 trades